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Acrosyringium Is the Main Site of the Vesicle/Pustule
Formation in Palmoplantar Pustulosis
Masamoto Murakami1, Takaaki Ohtake2, Yoshimune Horibe3, Akemi Ishida-Yamamoto1, Vera B. Morhenn4,
Richard L. Gallo4 and Hajime Iizuka1
Pustulosis palmaris et plantaris or palmoplantar pustulosis (PPP) is a refractory pustular eruption on the palms
and soles with unknown etiology. Numerous eccrine sweat pores exist on the palms and soles, suggesting the
involvement of eccrine sweating in the pathogenesis of PPP. To the best of our knowledge, however, no definite
abnormality in sweating has been documented in PPP. Accordingly, we analyzed the eccrine sweat duct
involvement in the mechanism of vesicle formation in PPP. Dermatoscopy showed that PPP vesicles are located
on the top of the ridges but not in the furrows. The sweat secretion in the lesional area was much lower than
that in the nonlesional area, with or without pain stimulation to induce sweating. Immunostaining of horizontal
sections of the lesions using antibodies against gross cystic disease fluid protein-15 (GCDFP-15) and epithelial
membrane antigen (EMA) showed that these markers were localized in the cells lining the intraepidermal
vesicles. Although the sweat antimicrobial peptides, dermcidin and human cathelicidin antimicrobial peptide 18
(hCAP-18)/LL-37, were detected in the fluid of the vesicles/pustules, neither dermcidin nor hCAP-18/LL-37 were
overexpressed by neighboring keratinocytes. These findings suggest that the acrosyringium may be involved
as the main site of the vesicle formation in the pathomechanism of PPP.
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INTRODUCTION
Pustulosis palmaris et plantaris or palmoplantar pustulosis
(PPP) is a chronic pustular dermatitis characterized by
palmoplantar intraepidermal vesicles filled with neutrophils
(Uehara and Ofuji, 1974). Although it is a common
skin disease often recalcitrant to available treatments, the
pathogenesis remains unknown. Numerous eccrine sweat
pores exist on the palms and soles, and several reports suggest
the involvement of eccrine sweating in the pathogenesis of
PPP (Krieg et al., 1992; Eriksson et al., 1998). To the best
of our knowledge, however, no definite abnormality in
sweating has been documented in PPP.
The eccrine sweat gland is a secretory as well as an
excretory organ. Although the sole function of sweat has been
considered to be thermoregulation during exposure to a hot
environment or during physical exercise, recent evidence
indicates that it has a role in the innate immune response.
Previously, two major classes of antimicrobial peptides were
identified in mammalian skin: cathelicidins (Zanetti et al.,
1995; Gallo et al., 1997; Nizet et al., 2001) and b-defensins
(Harder et al., 1997; Stolzenberg et al., 1997; Ali et al., 2001).
Cathelicidins, which are similar to many other antimicrobial
peptides, are synthesized as a preproprotein (Zanetti et al.,
1995). The only cathelicidin in humans is human cathelicidin
antimicrobial peptide (hCAP-18)/LL-37 (Agerberth et al., 1995;
Frohm et al., 1997) and it is expressed in leukocytes as well as
on a variety of epithelial surfaces. The hCAP-18/LL-37 has
been detected in human skin keratinocytes, but only at the site
of inflammation, suggesting that this antimicrobial peptide
functions primarily in response to injury rather than modulating
colonization of the skin’s surface (Frohm et al., 1997). Another
antimicrobial peptide, dermcidin, was recently detected in the
human sweat gland, suggesting that sweat may have an
additional important role in protection against various bacteria
(Schittek et al., 2001). Recently, we have shown the expression
of hCAP-18/LL-37 in eccrine sweat glands (Murakami et al.,
2002), which confirms the role of antimicrobial peptides in
protecting the body surface through innate immunity.
To dissect the involvement of the eccrine sweat duct in the
pathomechanism of vesicle formation in PPP, a possible
abnormality in the process of sweating was analyzed in early
lesions of PPP. Because the vesicle formation can be rapidly
induced by infection, stress, and so on, it is plausible to
speculate that the preexisting acrosyringium is involved in the
formation of the lesion. Our data provide a support for
the hypothesis that an abnormality in sweating initiates the
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formation of vesicles, suggesting a pathophysiological
mechanism for PPP.
RESULTS
PPP vesicles were located on the ridges of palmar skin
Dermatoscopy clearly showed that small vesicles and vesico-
pustules were located in a linear manner on the top of the
ridges but not in the furrows of the palmar skin (Figure 1).
Some large vesicles or pustules extended into the furrows.
Sweat secretion in the lesional area was decreased compared
with that in the nonlesional area
Sweat secretion was compared between the lesional and
nonlesional areas of the palmar skin. At the time of measure-
ment, the patient’s palm showed several small vesicles with
a few pustules. Sweat volume in the lesional area (B) was
much lower than that in the non-lesional area (A) or the
contralateral healthy palm(s) (Figure 2). The sweat volume
in the nonlesional area was increased after pain stimulation,
whereas that in the lesional area remained low.
Small vesicles were located in/and around the epidermal sweat
ducts in the early lesions
PPP vesicles were located within the epidermis, with typical
pustule formation (Figure 3). Keratinous material in the
acrosyringium was also observed (Figure 3a). A small vesicle
related to acrosyringium could be observed in the epidermis
(Figure 3b). The vesicle turned into a tiny pustule filled with
small round cells and neutrophils (Figure 3c). Microabscess
formation was observed in the epidermis with remarkable
inflammatory cell infiltration around the pustule (Figure 3d).
Finally, the lesion resolved to normal-appearing epidermis
(Figure 3e). Using horizontal sections, immunostaining with
gross cystic disease fluid protein 15 (GCDFP-15) and
epithelial membrane antigen (EMA) showed that these signals
were localized to the acrosyringium showing pores in the
Figure 1. Dermatoscopic findings of the palm of palmoplantar pustulosis
(PPP). (a) The palm of the patient with PPP shows small vesicles, small
pustules, desquamation, and erythema. (b) Dermatoscopy shows that many
vesicles of various sizes are located on the top of the ridge together with large
pustules.
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Figure 2. Lesional area shows decreased sweating compared with the
nonlesional area. (a)The 2-minute sweat volume was measured from the
nonlesional (A) and lesional area of palmoplantar pustulosis (PPP) (B) as well
as from a healthy palm. Basal sweat secretion of the lesional area was much
lower than that of the nonlesional area and of the healthy palms (Po0.05).
After pain stimulation, sweat secretion was increased significantly in the
nonlesional area and the other healthy palm (b) but not in the lesional area.
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epidermis and the lining cells of the intraepidermal vesicles
(Figure 4).
Expression of dermcidin and hCAP-18/LL-37 was not increased
in the keratinocytes around the vesicle formation
Dermcidin and hCAP-18/LL-37 were detected in the sweat
duct in the stratum corneum in addition to the dermal eccrine
sweat ducts (Figure 5). However, neither dermcidin nor
hCAP-18/LL-37 was overexpressed in the keratinocytes around
the vesicles (Figure 5). The hCAP-18/LL-37 was abundantly
expressed in the polymorphonuclear neutrophils (PMNs) in the
pustules but dermcidin was not detected (data not shown).
The expression of dermcidin and hCAP-18/LL-37 in PPP
vesicles/pustules
The sweat antimicrobial peptides, dermcidin and hCAP-18/
LL-37, were detected in the PPP vesicles/pustules (Figure 6).
Dot blots performed for the detection of dermcidin showed
positive signals in the PPP vesicles/pustules. The hCAP-18/LL-
37 western blots showed three bands (18 kd, full length;
15 kd, intermediate sized; and 4.5 kD; mature form), as was
already reported previously in sweat (Murakami et al., 2002).
All five samples of vesicles/pustules showed the same result,
and the representative data are shown in the figure.
The hCAP-18/LL-37 mRNA was not upregulated in lesional
PMNs
PMNs are known to contain hCAP-18/LL-37. To dissect the
origin of hCAP-18/LL-37 proteins, LL-37 mRNA expression in
the lesional and blood PMNs (L- and B-PMNs) were analyzed
with both reverse transcription-PCR and real-time PCR
(Figure 6c). Both L- and B-PMNs contained hCAP-18/LL-37
mRNA. However, there was no significant difference in the
mRNA expression levels between L- and B-PMNs as assessed
by real-time PCR (Figure 6d). All five samples of PMNs
showed the same result, and the representative data are
shown in the figure.
DISCUSSION
The etiology of PPP remains unknown, and whether PPP and
localized pustular psoriasis are distinct entities is still
controversial (Christpher and Mrowietz, 2003; Griffiths
et al., 2004). However, typical PPP usually presents in
patients who do not have a personal or family history of
psoriasis. Furthermore, the absence of immunogenetic
associations of PPP with psoriasis suggests that PPP may
represent a separate and distinct entity (Christpher and
Mrowietz, 2003; Griffiths et al., 2004). Our dermatoscopic
findings as well as our documentation of reduced local sweat
volume in the lesional area(s) are consistent with the notion
that the acrosyringium specifically is involved in the
pathogenesis of PPP (Eriksson et al., 1998). GCDFP-15, a
conventional marker for the apocrine gland, also cross-reacts
Figure 3. The palmoplantar pustulosis (PPP) lesion begins at the site
of the acrosyringium. The PPP lesion shows various histopathological
features (a–e). (The arrows indicate acrosyringium and dermal sweat duct.)
Hematoxilin and eosin (H&E) staining, original magnifications: (a, b, c, e)
200 and (d)  40. Bar¼50 mm.
Figure 4. The cells lining the vesicles express the same protein expression as
the acrosyringium. Immunostaining of horizontal sections using both gross
cystic disease fluid protein 15 (GCDFP-15) (a–c) and epithelial membrane
antigen (EMA) (d, e) shows expression of both proteins in the normal
eccrine ducts (acrosyringium) that appears similar to pores in the epidermis
(positive control) and the lining cells (arrows) of the vesicles. (f) Preimmune
IgG was used instead of the dermcidin or human cathelicidin antimicrobial
peptide 18 (hCAP-18)/LL-37 antibodies as a negative control. Original
magnifications: (a, d, e)  100, (b)  40, and (c)  400. Bar¼50 mm.
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with the eccrine glands (Viacava et al., 1998). Our results
document that the lining cells of the vesicles are positive for
GCDFP-15 in addition to EMA, suggesting that the main
component of the vesicles could be enlarged or destroyed
acrosyringium.
Several histopathological studies regarding the origin of
PPP have been published (Uehara and Ofuji, 1974). In brief,
the first phase of this disease is characterized by spongiosis or
epidermal vesicle formation followed by the purulent
eruption during the second phase. The pustulation begins
when direct contact between the blister fluid and the stratum
corneum occurs (Uehara and Ofuji, 1974).
Investigations on the mechanism of the formation of
subcorneal sterile pustules have focused on the chemotactic
factors for PMNs (Bruch-Gerharz et al., 1996; Gillitzer et al.,
1996; Kulke et al., 1996; Ozawa et al., 2005), which include
IL-8 and components of complement (Anttila et al., 1992;
Ozawa et al., 2005). Immunohistochemical studies showed
that intracellular epidermal IL-8 was consistently detected in
both PPP and psoriasis but not in nonlesional or healthy
control skin. HuMab 10F8, which to our knowledge is a
previously unreported human mAb against IL-8, significantly
reduced clinical disease activity of PPP by inhibiting the
formation of fresh pustules (Skov et al., 2008). C3b was also
detected on the subcorneal keratinocyte cell membranes
(Ozawa et al., 2005), suggesting that complement is also
responsible for the intraepidermal migration of PMNs
(Ozawa et al., 2005).
Recent evidence indicates that skin antimicrobial peptides
are also chemotactic for PMNs (De et al., 2000). The
peptides, such as cathelicidin (Frohm et al., 1997; Gallo
et al., 1997; Bals et al., 1998), defensins (Ali et al., 2001), and
dermcidin (Schittek et al., 2001), are essential elements of the
epithelial defense system that participate in a variety of
immune mechanisms in both a direct and indirect manner
(Gallo et al., 2002; Zasloff, 2002). For human sweat glands,
the constitutive expression of dermcidin and inducible
expression of cathelicidin have been documented (Schittek
et al., 2001; Murakami et al., 2002). Using these peptides as a
marker for sweat, we obtained the evidence that the PPP
patients had an abnormal sweat secretion.
Dot-blot and western blot analyses showed that the vesicle
and pustule fluid contains the same antimicrobial peptides
that are found in sweat. It has been reported that dermcidin is
continuously secreted in the eccrine sweat but is not induced
during inflammation (Schittek et al., 2001; Rieg et al., 2004),
whereas cathelicidins are induced under inflammatory
conditions such as psoriasis and wound healing (Frohm
et al., 1997; Gallo et al., 2002). It is known that the source of
cathelicidin is the granules of the PMNs (Sorensen et al.,
Figure 5. Neither dermcidin nor human cathelicidin antimicrobial peptide
18 (hCAP-18)/LL-37 is overexpressed in the keratinocytes around the
vesicles. Both (a, b) dermcidin and (c, d) hCAP-18/LL-37 were detected in the
sweat duct in the stratum corneum in addition to the eccrine sweat ducts in
the dermis (arrows). (b, d) However, keratinocytes around the vesicles show
no dermcidin or hCAP-18 overexpressions. (e) Preimmune IgG was used
instead of the dermcidin or hCAP-18/LL37 antibody as a negative control.
Original magnification  100, bar¼ 50 mm.
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Figure 6. Palmoplantar pustulosis (PPP) vesicles/pustules contain both
dermcidin and hCAP-18/LL-37; however, no upregulation of LL-37 mRNA in
lesional PMNs of PPP was seen. (a) A western blot for human cathelicidin
antimicrobial peptide 18 (hCAP-18)/LL-37 shows three bands (18, 15, and
4.5Kd), suggesting the sweat hCAP-18/LL-37 expression pattern as previously
described. Polymorphonuclear leukocytes of the peripheral blood (PMN) and
LL-37 synthetic peptide (LL-37) were applied as positive controls, and
dermcidin as a negative control, respectively (these lanes were not originally
run next to each other). (b) The dot blot showed that vesicles from PPP contain
dermcidin. Dermcidin synthetic peptide (derm) was applied as a positive
control, and dermcidin precursor protein Y-P 30 (Y-P 30) and PMN were
applied as negative controls. LL-37 mRNA expression in the lesional and
blood PMNs (L- and B-PMNs) were analyzed with (c) reverse transcription-
PCR (RT-PCR) and (d) real-time PCR. (c) RT-PCR showed that both L- and
B-PMNs contain hCAP-18/LL-37 mRNA. (d) Real-time PCR showed no
statistically significant difference in the mRNA expression levels between
L- and B-PMNs.
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1997, 2001). Therefore, we analyzed whether the cathelici-
din also comes from the surrounding keratinocytes of the
lesion. Both dermcidin and hCAP-18/LL-37 were documen-
ted in the sweat duct in the stratum corneum in addition to
the eccrine sweat ducts in the dermis, as reported previously
(Schittek et al., 2001; Murakami et al., 2002). However, no
dermcidin or hCAP-18/LL-37 overexpressions were detected
in keratinocytes around the vesicles. This suggests that
neither dermcidin nor hCAP-18/LL-37 in the fluid came from
the surrounding keratinocytes. Quantitative real-time PCR
also disclosed no significant difference in the mRNA
expression levels between L- and B-PMNs. On the basis of
these findings, we conclude that cathelicidin in the vesicle
fluid originated mainly from the sweat-derived contents of the
acrosyringium.
Eriksson et al. (1998) recently performed a clinical and
immunohistological study of PPP, and proposed that the
acrosyringium was possibly involved in this disease. This
hypothesis was based on the observation that the epidermal
eccrine duct structure was not present in any of the
specimens from PPP, whereas it was present in all of the
control specimens (Eriksson et al., 1998). In contrast, our
results clearly show the involvement of the acrosyringium in
the PPP vesicle formation, suggesting that the disease
originates from the acrosyringium. However, it is still unclear
why the acrosyringium is involved at the initiation of this
process, and whether external pathogens are involved in the
etiology of this disease. The mechanistic insight of why
pustule is developed only in PPP, but not in other sweat-
related diseases such as miliaria, remains unknown. Possibly,
the thick horny layer of palms and soles is critically involved
in the typical pustule formation of PPP. These issues remain
to be clarified to dissect the pathomechanism of PPP in the
future studies.
MATERIALS AND METHODS
PPP volunteers
The study was conducted according to the Declaration of Helsinki
Principles. After obtaining approval from the ethics committee of
Asahikawa Medical College, 15 volunteer patients (13 females and 2
males; mean age: 62.7±18.5 years; range 33–82) with a 2- to
10-year history of PPP were recruited for this study with informed
consent. They had not been treated with any medications before.
These patients were diagnosed by at least two board-certified
dermatologists according to the clinical features. After obtaining
informed consent, 15 samples for biopsy and 5 samples for blood
and lesional vesicle/pustule samples were collected.
Dermatoscopy
The palms and soles of the patients were examined using a
dermatoscope (Derma 9500C; KOS Medical K. K., Kanagawa,
Japan). The pictures were recorded and stored as digital files.
Dermatoscopy work was completed by a dermatologist and then
checked by another board-certified dermatologist.
Sweat measurement
To see whether a sweat secretion problem existed on the lesional
area of the skin, palmar sweat volume was measured using a
cutaneous evaporation meter (portable sweat meter TS-100;
TECHNO SCIENCE, Tokyo, Japan) according to the ventilation
capsule method (Tomioka et al., 2005; Ohshima et al., 2008), and
was compared with nonlesional areas. Probe (1 cm2) of the sweat
meter was applied on the target skin area, and the 2-minute sweat
volume was measured at both the lesional and nonlesional areas on
the palms of the PPP patients. To see the increase in the pain-
induced sweating, the total 2-minute sweat volume after pin-prick
stimulation was also measured in both lesional and nonlesional
areas. The measurement was repeated three times on the same
patient.
Tissue and vesicular fluid sampling
Excisional biopsies (approximately 10mm in size) were taken from
palmar lesions of 15 PPP cases with informed consent. The
specimens were fixed in 10% buffered formalin overnight and were
embedded in paraffin blocks for routine pathological diagnosis. The
4mm sections were prepared for hematoxilin and eosin, as well as for
immunostaining. Horizontal slices of 5 mm thickness were also
prepared for additional immunostaining to distinguish the acrosyr-
ingium (vide infra).
Using a micropipetter, the fluid obtained from the vesicles or vesico-
pustules was collected from five patients immediately after cutting the
top off the lesion and was placed into a 1.5ml centrifuge tube. Several
vesicles in the area of the lesion were collected and mixed together. In
all, 1ml of phosphate-buffered saline (PBS) was added and the sample
was centrifuged at 15,000 r.p.m. for 5minutes and spun down. The
supernatant was then lyophilized with a Speed Vac (Savant Instruments,
Inc, Farmingdale, NY) overnight, and the pellet was resuspended in
50ml of double-distilled water for western blot and dot-blot analyses. All
samples were then stored at 80 1C until use.
L-PMN collection from the lesion
For western blot and real-time PCR analyses, PMNs from palmar
pustules (L-PMNs) were collected from five patients. The cells were
obtained from the lesion with a micropipette after a small incision
into the pustule. Collected L-PMNs were washed with PBS three
times and then re-suspended in 100 ml of PBS. Using venipuncture,
4ml of blood was drawn. B-PMNs were isolated and then processed
with Polymorphprep (Axis-Shield PoC AS, Oslo, Norway) according
to the manufacture’s instruction. The samples were re-suspended in
100ml of PBS. All samples were stored at 80 1C until use for RNA
and protein extractions.
Antibodies
Rabbit polyclonal antibody to LL-37 used for immunostaining
was developed against full-length LL-37 (Murakami et al., 2005).
Mouse monoclonal antibody to dermcidin (G-18; Santa Cruz
Biotechnology, Santa Cruz, CA), mouse monoclonal antibody
to EMA (clone E29; DAKO, Glostrup, Denmark), and mouse
monoclonal antibody to GCDFP-15 (BRST-2, clone D6; Signet
Laboratories, Dedham, MA) were purchased.
Synthetic peptides for LL-37 and dermcidin
Synthetic LL-37 was commercially prepared by Peptide Institute
(Osaka, Japan), and synthetic dermcidin and its precursor Y-P30
(Schittek et al., 2001), as a negative control, were prepared by
Synpep (Dublin, CA). Peptide amino acid sequences were
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LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES for LL-37, SSLLEK
GLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSVL for
dermcidin, and YDPEAASAPGSGNPCHEASAAQKENAGEDP for
Y-P30. The synthetic peptides were purified to over 95% by HPLC
and their identity was confirmed by mass spectrometry, respectively.
Western blot analysis
Protein extraction from PMN samples was performed by acidifica-
tion with 1% trifluoroacetic acid and 1M hydrochloric acid. In brief,
500ml of 1% trifluoroacetic acid and 1M hydrochloric acid solution
was added to the PMN samples, vortexed well to destroy the
cells, and then incubated at room temperature (RT) for 30minutes.
After centrifuging, the supernatant was collected, concentrated by
lyophilization, and resuspended in 50 ml of double-distilled water.
All samples were stored at 30 1C until use. Protein samples from
PMNs and the vesicle/pustule fluids (10 ml) were separated by 16%
Tricine gel (Invitrogen, Carlsbad, CA), respectively, and then trans-
ferred onto a polyvinylidene difluoride membrane (immobilone-P;
Millipore, Bedford, MA). A total of 10 nmol of LL-37 (as a positive
control) and dermcidin (as a negative control) synthetic peptides
were also applied, respectively. The membrane was blocked with
5% nonfat milk in 0.1% TTBS (0.1% Tween-20/tris-buffered saline
(TBS)) for 60 minutes at RT, and then rabbit anti-LL-37 polyclonal
antibody (1:5,000 in the 5% nonfat milk in 0.1% TTBS) was applied
on the membrane overnight 4 1C. After washing the membrane three
times with 0.1% TTBS, horseradish peroxidase-labeled goat anti-
rabbit IgG polyclonal antibody (1:5,000 in the blocking solution;
Bio-Rad Laboratories, Hercules, CA) was incubated with the
membrane for 60minutes at RT. After washing the membrane with
0.1% TTBS, the membrane was immersed in enhanced chemilumi-
nescence solution (Western Lightning Chemiluminescence Reagents
Plus; New Lifescience Products, Boston, MA) for 60 seconds, and
was then visualized with LAS-3000 imaging system (Fujifilm, Tokyo,
Japan) according to the manufacture’s instruction.
Dot-blot analysis
Dermcidin expression in the PPP fluid was evaluated by dot-blot
analysis. In brief, 1ml of fluid samples from the PPP patient was
applied onto a nitrocellulose membrane with 32 nmol of dermcidin.
The Y-P30 and LL-37 synthetic peptides were used as negative
controls. After air-drying the membrane, the immunoreaction was
visualized as described above with anti-dermcidin antibody in the
blocking solution overnight at 4 1C. After washing the membrane
with 0.1% TTBS, a horseradish peroxidase-labeled goat anti-mouse
IgM polyclonal antibody (1:5,000 in the blocking solution; Santa
Cruz Biotechnology) was applied as the second antibody for
60minutes at RT. After washing with 0.1% TTBS, the membrane
was immersed in enhanced chemiluminescence solution for
60 seconds and was then visualized with LAS-3000 imaging system.
Immunohistochemistry
Tissue sections were immersed in PBS after deparaffinization, and
endogenous peroxidase activity was blocked by incubating with
0.3% H2O2 in methanol for 30minutes. After washing with PBS, the
immunostaining with rabbit anti-LL-37 (1:100) and mouse anti-
dermcidin (1:100) antibodies was performed using Histofine SAB-PO
kits (Nichirei Biosciences, Tokyo, Japan) according to the manu-
facture’s instruction. To visualize the sweat pore structure,
horizontal slices were obtained and stained with mouse anti-EMA
(1:100) and GCDFP-15 antibodies (1:100). As a negative control,
the polyclonal antibody and monoclonal antibodies were replaced
by normal rabbit and mouse preimmune IgG diluted with PBS
containing 3% BSA at the same protein concentration used for the
primary antibodies. All procedures were carried out at RT except for
the first antibody incubation (4 1C, overnight).
Reverse transcription-PCR and real-time quantitative PCR
Total RNA was extracted from PMNs using RNeasy Mini kit (Qiagen,
Valencia, CA), and complementary DNA was prepared from 1mg of
total RNA using iScript complementary DNA synthesis kit (Bio-Rad
Laboratories) according to the manufacture’s instruction. PCR
amplification of LL-37 was performed with the forward primer
(50-GATAACAAGAGATTTGCCCTGCTG-30) and the reverse primer
(50-TTTCTCAGAGCCCAGAAGCCTG-30) for a 173-bp product.
Amplification of 18S rRNA was carried out in parallel for all the
samples with QuantumRNA classic 18S internal standard kit
(Ambion, Woodward Austin, TX). PCR protocol was denaturation
at 90 1C for 10minutes, followed by 35 cycles of amplification with
denaturation at 94 1C for 30 seconds, primer annealing at 50 1C for
30 seconds, and extension at 72 1C for 1minute. After the reverse
transcription-PCR, real-time quantitative PCR was performed using a
LightCycler 2.0 system (Roche Diagnostics, Manheim, Germany) to
compare the mRNA expression levels. RT reaction was performed in
2ml of DNA Master SYBR Green I (Roche) and 2ml of each 5 mM
primer as described above. Amplification of GAPDH was carried out
in parallel for all samples with LightCycler-primer set for Human
GAPDH (Roche Diagnostics). Thermal profile was as follows: 95 1C
for 10 seconds, 40 (94 1C for 15 seconds and 60 1C for 1minute).
Results were analyzed using the comparative Ct method, in which Ct
indicates the number of cycles required to reach an arbitrary
threshold (Dorschner et al., 2003).
Statistical analysis
The data of the sweat measurement and the real-time PCR were
evaluated using STATFLEX software (version 4.2; ARTEC, Osaka,
Japan). Nonparametric t-test (Mann–Whitney U-test) was applied to
compare differences between L- and B-PMNs. A Po0.05 was
considered to be significant.
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